MoonLake Immunotherapeutics Dividend

Dividend criteria checks 0/6

MoonLake Immunotherapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-2.8%

Buyback Yield

Total Shareholder Yield	-2.8%
Future Dividend Yield	0%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend updates

No updates

Recent updates

MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold

Oct 13

MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business

Aug 27

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

Jul 18

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

May 14

MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3

Feb 26

We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn

Jan 29

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

Oct 16

Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics

Jul 26

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if MLTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MLTX's dividend payments have been increasing.

Dividend Yield vs Market

MoonLake Immunotherapeutics Dividend Yield vs Market

How does MLTX dividend yield compare to the market?
Segment	Dividend Yield
Company (MLTX)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.5%
Industry Average (Biotechs)	2.2%
Analyst forecast (MLTX) (up to 3 years)	0%

Notable Dividend: Unable to evaluate MLTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MLTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate MLTX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MLTX has not reported any payouts.

MoonLake Immunotherapeutics Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold

MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business

New major risk - Revenue and earnings growth

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

New major risk - Revenue and earnings growth

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from Both FDA and EMA on Path for the Phase 3 Program for the Nanobody Sonelokimab in Psoriatic Arthritis

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

MoonLake Immunotherapeutics, Annual General Meeting, Jun 05, 2024

MoonLake Immunotherapeutics, Annual General Meeting, Jun 05, 2024

New major risk - Revenue and earnings growth

Moonlake Immunotherapeutics to Present MIRA Trial Data of Nanobody Sonelokimab in Hidradenitis Suppurativa as A Late Breaker At the AAD Annual Meeting 2024

MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn

High number of new and inexperienced directors

Chief Financial Officer notifies of intention to sell stock

New major risk - Shareholder dilution

New minor risk - Share price stability

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

MoonLake Immunotherapeutics Announces the Full Dat Datasets from its 24-Week MIRA Clinical Trial, Establishing the Nanobody(R) Sonelokimab as Highly Promanded Therapeutics for Hidradenitis Suppurativa

Moonlake Immunotherapeutics Ag Announces Phase 2 Mira Primary Analysis Trial Results for Nanobody®? Sonelokimab in Hidradenitis Suppurativa to Be Presented At the European Academy of Dermatology and Venereology Congress

Price target increased by 12% to US$67.91

Price target increased by 12% to US$60.60

Price target increased by 9.4% to US$58.10

New major risk - Financial position

New major risk - Share price stability

Price target increased by 34% to US$43.63

Price target increased by 8.4% to US$32.67

MoonLake Immunotherapeutics AG Completes Patient Enrollment and Randomization Ahead of Schedule in A Phase 2 Trial of the Nanobody(R) Sonelokimab in Moderate-To-Severe Hidradenitis Suppurativa

Moonlake Immunotherapeutics Screens First Patient in Phase 2 Study of the Nanobody® Sonelokimab in Active Psoriatic Arthritis

Moonlake Immunotherapeutics to Initiate Global Phase 2 Study of the Nanobody Sonelokimab in Patients with Active Psoriatic Arthritis

Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics

MoonLake Immunotherapeutics Starts Phase 2 Trial of the Nanobody® Sonelokimab in Patients with Moderate-To-Severe Hidradenitis Suppurativa

MoonLake Immunotherapeutics Announces the Publication of New Long-Term Disease Control Data from A Phase 2B Psoriasis Trial of the Nanobody® Sonelokimab

No independent directors

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies